Respiratory Viral Infections
6
0
0
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 6 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
50%
2 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (6)
APOs Associated With Respiratory Viral Infections Before and During Early Pregnancy
A Study to Assess the Safety of Live Intranasal Sendai Virus Vaccine in Children and Toddlers
MxA-Guided Antiviral Treatment in Respiratory Viral Infections
Respiatory Viral Infections in Patients with Multiple Myeloma
The Development of a Human Model of Respiratory Syncytial Virus Infection
Safety and Tolerability Study to Evaluate MEDI-534 in Children 6 to < 24 Months of Age